Pazopanib treatment of a platinum-resistant recurrence of a high-grade Sertoli cell tumor and assessment of the treatment response by FDG-PET/CT: A case report
Ovarian Sertoli cell tumors (SCTs) are rare sex cord tumors (Oliva et al., 2005). The standard treatment for high-grade SCTs is surgery followed by platinum-based chemotherapy. Although platinum-based chemotherapy is also an option for recurrent SCTs (Sigismondi et al., 2012), there is no establishe...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-05-01
|
| Series: | Gynecologic Oncology Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352578918300195 |
| _version_ | 1818137486808842240 |
|---|---|
| author | Kayo Inoue Hiroshi Tsubamoto Keiko Ishida-Nisigami Yoshitaka Torii Seiichi Hirota |
| author_facet | Kayo Inoue Hiroshi Tsubamoto Keiko Ishida-Nisigami Yoshitaka Torii Seiichi Hirota |
| author_sort | Kayo Inoue |
| collection | DOAJ |
| description | Ovarian Sertoli cell tumors (SCTs) are rare sex cord tumors (Oliva et al., 2005). The standard treatment for high-grade SCTs is surgery followed by platinum-based chemotherapy. Although platinum-based chemotherapy is also an option for recurrent SCTs (Sigismondi et al., 2012), there is no established chemotherapy regimen for platinum-resistant recurrent SCTs. The effectiveness of pazopanib in treating epithelial ovarian cancer has recently been reported (du Bois et al., 2014; Pignata et al., 2015). In the case described herein, pazopanib was used to treat the platinum-resistant recurrence of a high-grade Sertoli cell tumor, and the response was evaluated by 18F-fluoro-deoxyglucose positron emission tomography (FDG-PET)-computed tomography (CT). Written informed consent to reporting the case was obtained from the patient. |
| first_indexed | 2024-12-11T09:57:04Z |
| format | Article |
| id | doaj.art-80486030b50b43618dbc362a0545ee41 |
| institution | Directory Open Access Journal |
| issn | 2352-5789 |
| language | English |
| last_indexed | 2024-12-11T09:57:04Z |
| publishDate | 2018-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Gynecologic Oncology Reports |
| spelling | doaj.art-80486030b50b43618dbc362a0545ee412022-12-22T01:12:14ZengElsevierGynecologic Oncology Reports2352-57892018-05-01245456Pazopanib treatment of a platinum-resistant recurrence of a high-grade Sertoli cell tumor and assessment of the treatment response by FDG-PET/CT: A case reportKayo Inoue0Hiroshi Tsubamoto1Keiko Ishida-Nisigami2Yoshitaka Torii3Seiichi Hirota4Hyogo College of Medicine, Department of Obstetrics and Gynecology, Japan; Corresponding author.Hyogo College of Medicine, Department of Obstetrics and Gynecology, JapanHyogo College of Medicine, Department of Clinical Pathology, JapanHyogo College of Medicine, Department of Obstetrics and Gynecology, JapanHyogo College of Medicine, Department of Obstetrics and Gynecology, JapanOvarian Sertoli cell tumors (SCTs) are rare sex cord tumors (Oliva et al., 2005). The standard treatment for high-grade SCTs is surgery followed by platinum-based chemotherapy. Although platinum-based chemotherapy is also an option for recurrent SCTs (Sigismondi et al., 2012), there is no established chemotherapy regimen for platinum-resistant recurrent SCTs. The effectiveness of pazopanib in treating epithelial ovarian cancer has recently been reported (du Bois et al., 2014; Pignata et al., 2015). In the case described herein, pazopanib was used to treat the platinum-resistant recurrence of a high-grade Sertoli cell tumor, and the response was evaluated by 18F-fluoro-deoxyglucose positron emission tomography (FDG-PET)-computed tomography (CT). Written informed consent to reporting the case was obtained from the patient.http://www.sciencedirect.com/science/article/pii/S2352578918300195 |
| spellingShingle | Kayo Inoue Hiroshi Tsubamoto Keiko Ishida-Nisigami Yoshitaka Torii Seiichi Hirota Pazopanib treatment of a platinum-resistant recurrence of a high-grade Sertoli cell tumor and assessment of the treatment response by FDG-PET/CT: A case report Gynecologic Oncology Reports |
| title | Pazopanib treatment of a platinum-resistant recurrence of a high-grade Sertoli cell tumor and assessment of the treatment response by FDG-PET/CT: A case report |
| title_full | Pazopanib treatment of a platinum-resistant recurrence of a high-grade Sertoli cell tumor and assessment of the treatment response by FDG-PET/CT: A case report |
| title_fullStr | Pazopanib treatment of a platinum-resistant recurrence of a high-grade Sertoli cell tumor and assessment of the treatment response by FDG-PET/CT: A case report |
| title_full_unstemmed | Pazopanib treatment of a platinum-resistant recurrence of a high-grade Sertoli cell tumor and assessment of the treatment response by FDG-PET/CT: A case report |
| title_short | Pazopanib treatment of a platinum-resistant recurrence of a high-grade Sertoli cell tumor and assessment of the treatment response by FDG-PET/CT: A case report |
| title_sort | pazopanib treatment of a platinum resistant recurrence of a high grade sertoli cell tumor and assessment of the treatment response by fdg pet ct a case report |
| url | http://www.sciencedirect.com/science/article/pii/S2352578918300195 |
| work_keys_str_mv | AT kayoinoue pazopanibtreatmentofaplatinumresistantrecurrenceofahighgradesertolicelltumorandassessmentofthetreatmentresponsebyfdgpetctacasereport AT hiroshitsubamoto pazopanibtreatmentofaplatinumresistantrecurrenceofahighgradesertolicelltumorandassessmentofthetreatmentresponsebyfdgpetctacasereport AT keikoishidanisigami pazopanibtreatmentofaplatinumresistantrecurrenceofahighgradesertolicelltumorandassessmentofthetreatmentresponsebyfdgpetctacasereport AT yoshitakatorii pazopanibtreatmentofaplatinumresistantrecurrenceofahighgradesertolicelltumorandassessmentofthetreatmentresponsebyfdgpetctacasereport AT seiichihirota pazopanibtreatmentofaplatinumresistantrecurrenceofahighgradesertolicelltumorandassessmentofthetreatmentresponsebyfdgpetctacasereport |